



Media Release

Medienmitteilung

Communiqué aux Médias

Sandoz Inc.  
506 Carnegie Center Drive,  
Suite 400  
Princeton, NJ 08540  
Phone +1 609 627 8500  
Fax +1 609 627 8682  
[www.us.sandoz.com](http://www.us.sandoz.com)

### **Sandoz launches generic version of Zyrtec-D®**

**Princeton, New Jersey; March 6, 2008** -- Sandoz introduced cetirizine hydrochloride/pseudoephedrine hydrochloride, a generic version of Zyrtec-D®, in the United States today. Cetirizine hydrochloride/pseudoephedrine hydrochloride extended release tablets, in 5 mg/20 mg strength, are an antihistamine/decongestant combination available without prescription to patients aged 12 years and older for relief from indoor and outdoor allergy symptoms.

Sandoz also introduced cetirizine hydrochloride tablets for treatment of allergies and hives, a generic version of Zyrtec®, as well as cetirizine hydrochloride chewable tablets, a generic version of Children's Zyrtec®, in the US earlier this winter. These products are available in 5 mg and 10 mg strengths without prescription.

#### **About Sandoz**

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 950 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (US) In 2007, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.2 billion

#### **Disclaimer**

The foregoing release may contain forward-looking statements regarding potential additional marketing approvals or future sales of cetirizine hydrochloride/pseudoephedrine hydrochloride and cetirizine hydrochloride. Any such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with cetirizine hydrochloride/pseudoephedrine hydrochloride and cetirizine hydrochloride to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that cetirizine hydrochloride/pseudoephedrine hydrochloride and cetirizine hydrochloride will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. Management's expectations regarding cetirizine hydrochloride/pseudoephedrine hydrochloride and cetirizine hydrochloride



could be affected by various risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

\* \* \*

**For further information**

Sandoz US Communications:

Charles A. Bruns

609.627.8881

Zyrtec-D®, Zyrtec®, and Children's Zyrtec® are registered trademarks of Pfizer Inc.